Is AppFolio (APPF) a Solid Growth Stock? 3 Reasons to Think "Yes"
By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.
However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.
AppFolio (APPF) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.
Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
Here are three of the most important factors that make the stock of this property management software maker a great growth pick right now.
Earnings Growth
Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for AppFolio is 15%, investors should actually focus on the projected growth. The company's EPS is expected to grow 17.9% this year, crushing the industry average, which calls for EPS growth of 17.6%.
Cash Flow Growth
Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds.
Right now, year-over-year cash flow growth for AppFolio is 170.5%, which is higher than many of its peers. In fact, the rate compares to the industry average of -18%.
While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 16.5% over the past 3-5 years versus the industry average of 15%.
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for AppFolio have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.3% over the past month.
Bottom Line
While the overall earnings estimate revisions have made AppFolio a Zacks Rank #2 stock, it has earned itself a Growth Score of B based on a number of factors, including the ones discussed above.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination indicates that AppFolio is a potential outperformer and a solid choice for growth investors.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AppFolio, Inc. (APPF) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Aurora Cannabis Inc. (ACB) Becomes Medical Market Powerhouse with 93% Sales Jump
We recently compiled a list of the 12 Cheap Pot Stocks to Buy According to Hedge Funds. Aurora Cannabis Inc. stands fourth on our list. Aurora Cannabis Inc. (NASDAQ:ACB), a prominent Canadian medical cannabis company, is strengthening its global footprint by focusing on international markets, particularly in Europe and Australia. The company has shifted away from recreational cannabis, positioning itself as a leader in the medical segment with strong fiscal results, reporting a 93% year-over-year increase in global medical cannabis revenue, which has now surpassed its domestic Canadian sales. Australia has become a key growth market where the company ranks as the second-largest supplier, while Germany's progressive cannabis laws offer further expansion opportunities. Aurora Cannabis Inc. (NASDAQ:ACB)'s growing international presence and improving fundamentals have placed it among cheap pot stocks to buy, especially for investors seeking value in the medical cannabis space. Its international growth is underpinned by a debt-free cannabis business, positive adjusted EBITDA, and a renewed focus on profitability, marking a notable turnaround. The company continues to engage shareholders, with its 2025 Annual General and Special Meeting scheduled for August 8. A laboratory filled with medical cannabis research equipment and supplies. Beyond financials, the business remains committed to social responsibility through initiatives like 'Strains for Heroes,' which develops medical cannabis products for veterans in collaboration with the community. Five percent of net profits from these products are donated to veteran-focused organizations, demonstrating the company's commitment to both innovation and impact. While we acknowledge the potential of ACB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
BrightSpring Health Services Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BrightSpring Health Services (NASDAQ:BTSG) Second Quarter 2025 Results Key Financial Results Revenue: US$3.15b (up 15% from 2Q 2024). Net income: US$9.21m (down 54% from 2Q 2024). Profit margin: 0.3% (down from 0.7% in 2Q 2024). EPS: US$0.046 (down from US$0.10 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period BrightSpring Health Services Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) missed analyst estimates by 9.3%. Looking ahead, revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are down 4.3% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for BrightSpring Health Services (of which 1 is a bit unpleasant!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Universal Display Second Quarter 2025 Earnings: Beats Expectations
Universal Display (NASDAQ:OLED) Second Quarter 2025 Results Key Financial Results Revenue: US$171.8m (up 8.4% from 2Q 2024). Net income: US$67.3m (up 29% from 2Q 2024). Profit margin: 39% (up from 33% in 2Q 2024). The increase in margin was primarily driven by higher revenue. EPS: US$1.41 (up from US$1.10 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Universal Display Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Semiconductor industry in the US. Performance of the American Semiconductor industry. The company's shares are down 2.8% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Universal Display's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data